Bibliography
- Lee JC, Kumar S, Griswold DE, et al. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 2000;47:185-201
- Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999;5:439-48
- Dodeller F, Schulze-Koops H. The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells. Arthritis Res Ther 2006;8:205
- Lee MR, Dominguez C. MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005;12(25):2979-94
- Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: many are made, but few are chosen. Curr Opin Drug Discov Devel 2005;8(4):421-30
- Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5(10):929-39
- Hynes J Jr, Leftheri K. Small molecule p38 inhibitors: novel structural features and advances from 2002 – 2005. Curr Top Med Chem 2005;5(10):967-85
- Bayer AG. WO03076405; 2003
- Bayer AG. WO03053967; 2003
- ESM Technology: Enhancing Drug Performance. Chroma Therapeutics, October 2006. Available from: http://www.chromatherapeutics.com/powerpoint/Cell-Accumulation-Approach.pps#3 [Last accessed May 2008]
- Sweeney SE, Firestein GS. Mitogen activated protein kinase inhibitors: where are we now and where are we going? Ann Rheum Dis 2006;65(Suppl 3):83-8
- Cell accumulation approach, Chroma Therapeutics. Available from: www.chromatherapeutics.com/Cell-Accumulation-Approach.htm [Last accessed April 2008]
- Chroma R&D Pipeline, Chroma Therapeutics. Available from: http://www.chromatherapeutics.com/Product-Pipeline.htm [Last accessed April 2008]